| 2.68 0 (0%) | 04-28 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 73.42 |
1-year : | 116.91 |
| Resists | First : | 62.86 |
Second : | 100.09 |
| Pivot price | 87.11 |
|||
| Supports | First : | 2.62 |
Second : | 2.18 |
| MAs | MA(5) : | 76.83 |
MA(20) : | 87.28 |
| MA(100) : | 88.36 |
MA(250) : | 0 | |
| MACD | MACD : | -5.3 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 40.6 |
D(3) : | 58.5 |
| RSI | RSI(14): 7.3 |
|||
| 52-week | High : | 884.97 | Low : | 2.62 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AVTE ] has closed below the lower bollinger band by 42.6%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 969.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.79 - 2.81 | 2.81 - 2.83 |
| Low: | 2.57 - 2.61 | 2.61 - 2.63 |
| Close: | 2.64 - 2.7 | 2.7 - 2.73 |
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Mon, 28 Apr 2025
Jade Biosciences closes merger with Aerovate Therapeutics - biv.com
Mon, 28 Apr 2025
Jade Biosciences Completes Closing of Merger with Aerovate - GlobeNewswire
Mon, 21 Apr 2025
Aerovate Stockholders Approve Merger Proposal With Jade Biosciences - Nasdaq
Mon, 21 Apr 2025
Aerovate Therapeutics Stockholders Approve Proposed Merger with Jade Biosciences and All Related Proposals - PR Newswire
Wed, 09 Apr 2025
Aerovate Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Jade Biosciences - PR Newswire
Thu, 27 Mar 2025
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates JWN, AVTE, HEES on Behalf of Shareholders - The Malaysian Reserve
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 29 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 110.8 (%) |
| Shares Short | 131 (K) |
| Shares Short P.Month | 123 (K) |
| EPS | -59.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 90.62 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -36.2 % |
| Return on Equity (ttm) | -59.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.84 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -50 (M) |
| Levered Free Cash Flow | -35 (M) |
| PE Ratio | -0.05 |
| PEG Ratio | 0 |
| Price to Book value | 0.02 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.56 |
| Dividend | 2.4 |
| Forward Dividend | 0 |
| Dividend Yield | 89.5% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|